- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07533331
Testing Conversational Agents as a Digital Companion
Pilot Test the Digital Intervention and Research Protocols in a Small Clinical Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
There is a need and opportunity to improve the supports, transitions, and life outcomes of people with autism spectrum disorder (ASD). Autism affects about 5.4 million adults in America (2.2% or 1 in 45 adults) and at least 78 million people and their families worldwide.1,2 Estimates for children are similar (1 in 44). Classified as a neurodevelopmental disorder, autism typically manifests in early childhood before the age of 3 years and affects social and communication skills, behavior, and outcomes throughout the life span. Teenagers and adults with autism have higher rates of unemployment or underemployment, low participation in post-secondary education, and nearly 40% spend little or no time with friends. Although awareness and scientific interest has grown significantly over the past 20 years, many children and adults are not diagnosed until later in life and much more can be done to improve the life outcomes for people with autism. Large knowledge gaps exist, such as what support strategies are effective for whom and when, and which ones have long-term and meaningful impact. Essentially, the mechanisms of positive change in autism, both behavioral and neurobiological, are largely unknown. Because autism has major implications for lifelong outcomes, cost-effective, affordable and scalable support systems are key, yet missing for many individuals and families.
Given that autism is a complex, heterogenous developmental condition that changes with and affects development, The Lancet Commission on the future of care and clinical research in autism recently stated that single assessments and treatments are never sufficient in ASD. Ongoing assessments and personalized supports that focus on individual strengths and challenges in different contexts across the life span are needed. Meanwhile, autistic people, their family members and community organizations have called for greater emphasis on enhancing quality of life (QOL). The World Health Organization (WHO) defines QOL as "an individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards, and concerns". In response, investigators at the Center for Autism Research Center at Children's Hospital of Philadelphia leveraged the patient reported outcome measurement information system (PROMIS) developed by the NIH to comprehensively assess QOL in autism, across age groups and genders. The PROMIS Autism Battery (PAB) includes 18 self-report scales for adults that show profound differences between autistic and neurotypical adult samples across virtually all PAB domains, including subjective wellbeing (SWB), relationships (including supports, companionship and social isolation), emotional distress (including anxiety and depression), health (including sleep and mental health), and adulthood (including self-efficacy).
In response to these needs and to NIMH's special topic of interest to "Develop and test new and augment existing digital health interventions that are personalized, engaging, adaptive, sufficiently challenging, and optimal for maximizing real world functional improvements," Friendi.fi Corporation (Friendi.fi) is leveraging its AI-driven technology platform and conversational agent that works on mobile phones through standard SMS (Short Message Service) texting, to be a mobile digital companion to autistic people in early adulthood. The platform and agent is used to scale a strong theoretical and conceptual approach that has proven successful in meeting the individual needs and targeted outcomes of autistic students through a collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS). COMPASS considers the challenges and strengths of the individual and environment, as well as the balance between them. Critically, the role of the environment as an enabler (support) or barrier (challenge) to success lowers the burden on autistic individuals as a source of dysfunction. In this model, technology is viewed as an environmental support that builds on the strengths, needs, and goals of the individual.
AYA will be enrolled in a 10-week experiential trial using the novel digital coaching program and agent. The trial serves several purposes: (1) It will test the preliminary efficacy of the digital intervention by assessing within-person change over time. The trial is powered to detect a minimal important change (MIC) in the proposed standardized and normalized PAB measures; (2) The observed effect size will be used to finalize the sample size calculation for a properly-powered future randomized control trial (RCT); (3) By including a control group, the feasibility of all clinical and study protocols is tested prior to implementing the RCT. Twenty-six AYA will receive daily coaching via the digital agents (AGENT group) and twelve will receive traditional coaching using face-to-face meetings with human counselors (CONTROL group). In both groups, intervention delivery and patient-reported outcomes data are collected.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Chantal Kerssens, PhD
- Phone Number: 404-282-0378
- Email: chantal@friendi.fi
Study Contact Backup
- Name: Cheri Maggard, MA
- Phone Number: 404-282-0378
- Email: cheri@friendi.fi
Study Locations
-
-
Indiana
-
Bloomington, Indiana, United States, 47408
- Recruiting
- Indiana Institute on Disability and Community
-
Contact:
- Judith Gross, PhD
- Phone Number: 812-855-7484
- Email: jmsgross@iu.edu
-
Principal Investigator:
- Judith Gross, PhD
-
Muncie, Indiana, United States, 47306
- Recruiting
- Ball State University
-
Contact:
- Evette Simmons-Reed, PhD
- Phone Number: 765-285-2762
- Email: easimmonsree@bsu.edu
-
Principal Investigator:
- Evette Simmons-Reed, PhD
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Recruiting
- Norton Children's Autism Center502-588-0736 x 50608
-
Contact:
- Grace Kuravackel, PhD
- Phone Number: 50608 502-588-0736
- Email: grace.kuravackel@louisville.edu
-
Principal Investigator:
- Grace Kuravackel, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- formal autism diagnosis per qualified professional.
- holds a job, volunteers, or attends college/vocational school where they participate in regular course work, classrooms, settings.
- drives or independently uses public transportation/ride share.
- makes medical decisions and manages finances.
- purchases groceries and cooks meals.
- engages in leisure activities with peers.
- reads and comprehends spoken and written English.
- able to complete surveys and informed consent independently.
able and willing to identify a trusted informant (such as a good friend, parent proxy or mentor who knows them well) for additional context, if needed.
(11) 24/7 access to a personal mobile phone with SMS text capability.
Exclusion Criteria:
- an intellectual disability.
- serious mental illness requiring psychiatric evaluation, intervention or in-patient hospitalizations in the past month.
- suicidal ideation or attempts in the past month.
- diagnosed sleep disorder in the past month.
- pregnancy.
- planned absences that interfere with study participation.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AGENT
goal coaching intervention via digital companion
|
a collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS).
|
|
Active Comparator: CONTROL
goal coaching using traditional face-to-face meetings with human counselors and paper-and-pencil materials.
|
a collaborative model for promoting competence and success (COMPASS) combined with Goal Attainment Scaling (GAS).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Mental Health
Time Frame: 10 weeks
|
PROMIS Scale v1.2-Global Mental 2a: Patient-Reported Outcomes Measurement Information System, 2 items assessing overall mental health, emotional well-being, and quality of life.
Minimum possible standardized T-score: approximately 21; Maximum possible score: approximately 68.
Raw scores range from 2 to 10. Higher scores indicate a better outcome.
|
10 weeks
|
|
Anxiety
Time Frame: 10 weeks
|
PROMIS Short Form v1.0-Anxiety 4a.
Patient-Reported Outcomes Measurement Information System, 4 items assessing emotional distress related to fears, worries, nervousness experienced over the past 7 days.
Scored using IRT-based T-scores.
Minimum possible T-score approximately 40; Maximum possible score approximately 82.
Raw scores range from 4 to 20.
Higher scores indicate a worse outcome.
|
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Goal Attainment
Time Frame: 10 weeks
|
Goal Attainment Scale (GAS) which assesses the extent to which individualized goals are achieved over a specified period of time relative to an expected level of goal achievement, not absolute ability or symptom severity.
Scores range from 1 (no progress) to 5 (exceeds goal).
Higher scores indicate a better outcome.
|
10 weeks
|
|
Self Efficacy
Time Frame: 10 weeks
|
PROMIS_SF_v1.0_Self_Effic-General_4a.
Patient-Reported Outcomes Measurement Information System, 4 items assessing an individual's confidence in their ability to handle problems, achieve goals, and manage difficult or unexpected situations.
Scored using standardized T-scores.
Minimum possible T-score approximately 28; Maximum possible score approximately 69.
Raw scores range from 4 to 20.
Higher scores indicate a better outcome.
|
10 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Chantal Kerssens, PhD, Friendi.fi Corporation
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 14023 (City of Hope Medical Center)
- 5R44MH134719-03 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...Istituto Clinico HumanitasRecruitingAutism | Autism Spectrum Disorder (ASD) | Autism DisorderItaly
-
Istituto per la Ricerca e l'Innovazione BiomedicaRecruitingAutism | Autism DisorderItaly
-
University of NottinghamUniversity Hospitals of Derby and Burton NHS Foundation Trust; Lincolnshire...Not yet recruitingAutism Spectrum Disorder | Autism | Parent | Autism Disorder | Autism in Children | Parent Stress | Parent Mental Health | Autism Disorders and Maternal Stress | Parent SupportUnited Kingdom
-
Boston Children's HospitalRecruitingAutism Spectrum Disorder | Autism | Autism DisorderUnited States
-
The Children's Hospital of Zhejiang University...Not yet recruitingAutism | Autism Spectrum Disorder (ASD)China
-
Poznan University of Physical EducationCompletedAutism | Autism Spectrum Disorder (ASD)Poland
-
Greater Atlanta Integrative PediatricsRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Adia Med of Winter Park LLCRecruitingAutism Spectrum Disorder | Autism | ASD | Autism Spectrum Disorder (ASD)United States
-
Stanford UniversityJohn and Marcia Goldman FoundationNot yet recruitingAutism | Autism Spectrum Disorder (ASD)United States
-
Father Flanagan's Boys' HomeNational Institute on Deafness and Other Communication Disorders (NIDCD)Not yet recruitingAutism Spectrum Disorder | Autism | Autism, Susceptibility to, 6United States
Clinical Trials on self-directed goal coaching
-
Teachers College, Columbia UniversityRecruitingDepression | Anxiety | Distress, Emotional | Emotional DysfunctionUnited States
-
University of California, IrvineCompletedPostoperative ComplicationUnited States
-
National Taiwan University HospitalCompletedPostoperative Cognitive Dysfunction | AnesthesiaTaiwan
-
University of CalgaryUniversity of AlbertaCompleted
-
Medical University of South CarolinaTerminatedEsophageal CancerUnited States
-
Insel Gruppe AG, University Hospital BernUniversity of BernCompletedDelirium | Sarcopenia | Fall | Mobility Limitation | Hospital Acquired Condition | Immobility SyndromeSwitzerland
-
Morehouse School of MedicineHarvard Medical School (HMS and HSDM)Active, not recruitingChronic PainUnited States
-
Brno University HospitalCompleted
-
Technical University of MunichMassachusetts General Hospital; Beth Israel Deaconess Medical Center; Università...CompletedRehabilitation | Critical Care
-
Medical University of ViennaCompleted